Rheumatology-Rhumatologie
10.2K views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

Advances in lupus genetics and epigenetics : Current Opinion in Rheumatology

Advances in lupus genetics and epigenetics : Current Opinion in Rheumatology | Rheumatology-Rhumatologie | Scoop.it
From journals.lww.com - September 3, 2014 9:27 AM
Purpose of reviewGenome-wide association studies have identified more than 50 robust loci associated with systemic lupus erythematosus (SLE) susceptibility, and follow-up studies help reveal candidate causative genetic variants and their biological relevance contributing to the development of SLE...

Via Krishan Maggon
more...
No comment yet.
Sign up to comment
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

IFNα-KINOID (Neovacs) for Lupus

IFNα-KINOID (Neovacs) for Lupus | Rheumatology-Rhumatologie | Scoop.it
From neovacs.fr - August 21, 2014 5:30 AM

The IFNα-Kinoïd is an anti interferon alpha (IFNα) therapeutic vaccine developed for the treatment of lupus (or Systemic Lupus Erythematosus, SLE). 

Neovacs has shown that the self antibodies produced by administration of the IFNα-Kinoïd neutralize all 13 sub-types of IFNα in the serum of lupus patients. This breadth of activity supports the positioning of Neovacs’ therapeutic vaccine as a next-generation treatment for this disease. 

A phase I/II clinical trial of IFNα-Kinoïd in lupus patient was conducted in 2010-2011. Very promising final results of the study were presented during the American College for Rheumatology Annual Meeting-Chicago in 2011 and published in 2013 in Arthritis & Rheumatology.
Neovacs is currently searching for potential partners to continue clinical development of IFNα-Kinoïd.

 


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, August 16, 2014 9:41 PM

The French company has been looking for R&D partners for IFNα-Kinoïd since 2011. After Rontalizumab Phase II failure and discontinuation by Roche , it has become more difficult to fund lupus research. 
Sign up to comment
About Follow us Resources Terms Mobile Features
Facebook
X
LinkedIn